maravai lifesciences holdings glp-1 receptor agonist medications Harnessing Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon Full article: GLP-1 receptor agonists

The Government Accountability Office (GAO) released a report in 2023 examining how the patent and regulatory system for drug-device combinations may be delaying generic competition

Some people taking GLP-1 medications may experience digestive side effects, with these being the most common: Nausea, especially at the start or after a dose increase Heartburn or stomach discomfort after meals Constipation, which can occur as the body adjusts Diarrhea, which may be mild or bothersome Vomiting, sometimes along with nausea Most digestive side effects lessen as the body adjusts

The promising obesity outcomes enabled by drugs such as Wegovy have prompted other drug manufacturers to pursue their own development efforts to help claim their share of this unprecedented market opportunity

BozzettoLAnnuzziGRagucciMDi DonatoODella PepaGDella CorteGet al

tirzepatide is the active ingredient (generic drug name)